We have several cases of CI of around 0.7 in our cell-based studies, which are confirmed synergies in vivo and have been approved for clinical use.

For instance, the combination of dabrafenib and trametinib for patients with BRAF mutation and the combination of olaparib and cisplatin for ovarian cancer patients.